Repros Therapeutics Inc. (NASDAQ:RPRX) was downgraded by research analysts at Laidlaw from a “buy” rating to a “neutral” rating in a research note issued on Friday.

Shares of Repros Therapeutics (NASDAQ RPRX) opened at 0.395 on Friday. Repros Therapeutics has a one year low of $0.30 and a one year high of $2.48. The firm’s market cap is $10.56 million. The firm’s 50-day moving average price is $0.44 and its 200 day moving average price is $0.94.

Repros Therapeutics (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08. The business had revenue of $0.01 million during the quarter. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. Analysts predict that Repros Therapeutics will post ($1.07) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at

A hedge fund recently raised its stake in Repros Therapeutics stock. Renaissance Technologies LLC raised its position in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 7.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 716,413 shares of the biotechnology company’s stock after buying an additional 49,300 shares during the period. Renaissance Technologies LLC owned approximately 2.82% of Repros Therapeutics worth $946,000 as of its most recent filing with the SEC. 21.71% of the stock is currently owned by institutional investors and hedge funds.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with's FREE daily email newsletter.